An orphan drug status is given to medicines that show promise in treating, preventing, or diagnosing diseases affecting fewer than 200,000 people in the U.S.
Additional Investments by Syncona
Syncona also announced a £16.5 million investment in U.K. cancer therapy specialist Yellowstone Biosciences, acquiring a 60.9% stake in the business, which has been spun out from the University of Oxford.
iOnctura and the investors did not immediately respond to requests for comment.
